高血压病病机探讨及三草降压汤的降压作用与机理研究
|
摘要
高血压病是一种常见的慢性心血管疾病,不仅发病率高,而且具有病程长,病理机制复杂,并发症多等特点,常伴有心、脑、肾等重要脏器的损害,严重危胁着人类健康。因此,高血压病发病机理和治疗药物的研究,一直是国内外医学界研究的热点。越来越多的证据表明,中医药治疗高血压病,具有独特的优势。在长期的临床实践中,也积累了一些有效方剂。归纳分析高血压病的病机特点,系统评价临床有效方剂的疗效,阐明其降压机理,进而研制新的降压药物,为临床提供更有效的治疗方法,是中医药现代化的重要内容。
病机在中医理论中占有十分重要的地位。本课题将高血压的病机按照不同层次,分别讨论,然后探讨各层次间的关系,融会贯通,以期理清病机系统的脉络。
三草降压汤(SCD)是我校名老中医刘渡舟教授创制的经验方,经过大量临床观察证明对高血压病有效。本课题利用现代药理学的方法系统评价该方的降压作用,阐明其降压作用机理,以便为该方的开发和应用奠定现代研究的基础。
利用“病证结合动物模型”进行中医药的基础和应用实验研究,所得研究结果方能揭示辨证论治、方证相应等中医理论的科学内涵,体现中医药治疗的特色与优势。本课题通过宏观表征和行为学指标的观察与微观指标的测定,较系统地研究了自发性高血压大鼠(SHR)和肾性高血压大鼠(RHR)的证候属性,为建立适合中医药研究的动物模型提供了新思路。
目的
1探讨高血压病的病机及SCD治疗高血压的组方机理;
2评价SCD的降压作用;
3阐明SCD治疗高血压病的作用机理;
4初步辨析SHR与RHR模型的证候属性。
方法
1理论研究
通过整理高血压病病机文献,较系统地探讨高血压病病机;基于高血压气、血、脉失调的病机,浅析SCD的组方特点。
2实验研究
采用SHR和两肾一夹(2K1C)法制作的RHR动物模型;采用清醒状态下大鼠尾动脉间接测压法观察降压作用的时效、量效关系及连续给药的降压效果;运用宏观表征和行为学指标,研究SCD对动物模型的证侯属性的影响;运用放射免疫、生物化学的方法检测方药对血浆中的血压调节物质的影响;运用病理切片的方法观察对靶器官损害的影响。
结果
1理论研究
高血压病的病机可以分为基本病机,症状病机,疾病病机,证候病机及微观病机等几个不同层次,气、血失调和脉道不利是该病病机的关键。气、血、脉兼治是SCD的组方特点。
2实验研究
2.1 SCD对SHR大鼠的降压作用及其机理研究
(1) SCD对SHR单次给药的时效关系研究表明,SCD小、中、大3个剂量组时效特点相似,均在给药后4h达到最大降压效果,而后开始回升,8h接近给药前水平。量效关系研究则表明给药后4h,中、大剂量组血压均显著下降(p<0.05),降幅达10mmHg左右,小剂量组无降压作用。
(2) SHR模型组大鼠与正常组相比在14～18周内血压偏高(p<0.01),心率偏高(p<0.01),易激惹程度增加(p<0.05或p<0.01),痛阈提高(p<0.01),旋转时间偏低(p<0.01或p<0.05),眼球突出度偏高(p<0.01),体重偏低,18周龄时有显著性差异(p<0.05),神情较紧张,同笼大鼠间经常有打架现象,毛色发黄而无光泽,毛发脱落较多,小便颜色偏黄,大便颗粒较小、质地较干。
连续给药4周期间,SCD组与模型组相比在给药后血压极显著下降(p<0.01),心率没有明显改变,易激惹程度降低(p<0.01),痛阈无明显差别,旋转时间增加(p<0.05)。眼球突出度未见显著改善,体重无显著变化,紧张、打架现象减少,小便颜色较清,大便较湿润。
(3)病理形态上,SHR模型组可见心肌横径增粗;部分肾脏皮质可见肾小球硬化、萎缩,局部区域肾小球集中现象,间质中有淋巴细胞浸润;大脑皮层局部区域可见嗜神经细胞现象,脑软化等现象。连续给药4周的SCD组上述现象均较少见。
(4)与正常组相比,SHR模型组心脏指数和左心室指数均增加(p<0.01),血浆AngII水平偏低(p<0.01),ET升高(p<0.01),ANP降低(p<0.01),PRA、CGRP、NO含量无明显差异。
与SHR模型组相比,连续给药4周的SCD组的心脏指数和左心室指数无显著差异,血浆ET水平降低(p<0.01),ANP升高(p<0.01),NO升高(p<0.01),AngII、PRA、CGRP无明显变化。
2.2 SCD对RHR大鼠的降压作用及其机理研究
(1) SCD对RHR单次给药的时效关系研究表明,SCD小、中、大3个剂量组时效特点相似,均在给药后4h达到最大降压效果,而后开始回升,8h接近给药前水平。量效关系研究表明,给药后4h,小、中、大剂量组血压均显著下降(p<0.05或p<0.01),中剂量组降幅达17mmHg左右,大剂量组10mmHg,小剂量组6 mmHg。
(2) RHR模型组大鼠在造模后4周～8周期间与正常组相比血压偏高(p<0.01),心率偏高(p<0.01或p<0.05),痛阈偏高(p<0.05),体重偏低,18周龄时有显著性差异(p<0.01),精神较萎靡,毛色无光泽,小便色清,被抓持时遗尿现象较普遍,大便质软,腐臭味重。
连续给药4周期间,SCD组与模型组相比在给药后血压极显著下降(p<0.01),心率减慢(p<0.05),体重增加(p<0.05),痛阈增高(p<0.05),转台旋转时间增长(p<0.05),毛色不泽与遗尿现象亦有改善。
(3)病理形态上,RHR模型组可见心肌横径增粗;部分肾脏皮质可见肾小球硬化、萎缩,局部区域肾小球集中现象,间质中有淋巴细胞浸润,球旁动脉可见玻璃样变性;大脑皮层局部区域可见嗜神经细胞现象,脑软化等现象。连续给药4周后,SCD组上述现象均较少见。
(4)与正常组相比,RHR模型组心脏指数和左心室指数上均增加(p<0.01),血浆PRA水平偏高(P<0.01),AngII偏高(P<0.05),ANP偏高(p<0.01),ET、CGRP、NO无显著差异。
与模型组相比,连续给药4周后,SCD组的心脏指数和左心室指数无显著差异,血浆PRA水平降低(p<0.01),AngII降低(p<0.05),ET降低(p<0.05),NO升高(p<0.05),ANP、CGRP无明显变化。
2.3 SHR大鼠对SCD降压反应的个体差异初探
虽然多数个体给予SCD后血压明显降低,但有29%的SHR大鼠在给药后血压无明显变化,当增大或减小剂量时,这些对药物不敏感的大鼠血压仍没有显著变化。
结论
1气血失调和脉道不利是高血压病病机的关键,气、血、脉兼治是SCD配伍特点;
2 SCD具有明显的降压作用,并且其降压作用显示出一定时效、量效关系;
3 SCD可以改善SHR和RHR的宏观表征及行为,显示出其整体治疗效果;
4初步阐明了SCD的降压作用机理,发现SCD在两种高血压模型中作用机理不同;
5早期SHR对SCD降压反应存在个体差异。
Hypertension is a familiar chronic cardiovascular disease. Not only the incidence of hypertension is high, moreover, the course of the diseases is comparatively longer, its pathology mechanism is complex. This syndrome has many complications, that ofen associates with the damage of important viscera such as heart, brain, kidney and so on, which threatens the health of human being seriously. So the research on the pathogenesis of hypertension and curatives is one of the hotspots of international medical field all over the world. More and more proofs make it clear that T.C.M. has unique advantage on the therapy of hypertension and some available prescriptions have been accumulated in the long-term clinic practices. Reduction analysis of the pathology characteristics of hypertension, comprehensive evaluation the curative effect of clinic effective prescriptions, clarification the mechanism in treating , to study its mechanism in treating essential hypertension, thus development new therapy medicine of hypertension and providing more effective trerapy methods for clinic are important contents of modernization of T.C.M..
Pathogenesis possesses very important postion in T.C.M. theory. This study discussed pathogenesis of essential hypertension respectively according to different levels, then probed into the relationship of various levels in order to ascertain the skeleton venation of pathogenesis system.
San Cao Jiang Ya Tang (SCD) is an experience prescription formulated by famous old doctor of Chinese medicine Liu Du-zhou, a professor of our uviversity, the prescription has been proofed effective in treating hypertension. In this study we maked use of modern pharmacology, comprehensively evaluates this prescription’s effect on hypertension and clarifies its mechanism on therapy of hypertension so as to establish modern research foundation for the development and application of this prescription.
Only through foundmental and applied experiment research by using“animal model with combined syndromes and symptoms”, can the research results reveal the scientific meanings of T.C.M. theories such as treatment based on syndrome differentiation, prescriptions corresponding to syndromes and so on, representing the characterisctis and advantages of traditional chinese medicine. This study comprehensively researched symptom attributes of the spontaneously hypertensive rat (SHR) and the renal hypertensive rat (RHR), providing new thinking on setting up modern animal models for T.C.M. researches.
Objective
1 Discuss the mechanism of hypertension and SCD’s prescription theory in treating hypertension;
2 Evaluate SCD’s effect in treating hypertension;
3 Clarify SCD’s mechanism in treating hypertension;
4 Differentiate Syndrome attributes between SHR and RHR elementarily.
Methods
1 Theoretics research
Systemically discuss the pathogenesis of hypertension through organizing literatures about it.
Preliminary analysis the prescription theory of SCD based on maladjustment pathogenesis of Qi, blood and vessel in hypertension.
2 Experiment research
SHR and two-kindy, one clip (2K1C) RHR were used as animal model. Tail-artery blood pressure measurement for conscious rats was used to observe the time-effect, dose-effect and long-term treatment features of the medicine to the blood pressure of the rats.The effect of SCD to animal model was studied by observeing macro representations and behavior. The blood pressure regulating factors in the plasma was examined by the method of radioimmunoassay and biochemistry. The target-organ damage was observed by pathologic slices making.
Result
1 Theoretics research
Pathogenesis of hypertension can be divided into several different levels, such as basic pathogenesis, pathogenesis of representation, pathogenesis of disease, pathogenesis of syndromes, and micro pathogenesis. Maladjustment between Qi and blood and obstruct of the vessels are the key to the pathology mechanism of this disease. Prescription characteristics of SCD lies in that it can concurrently cure Qi, blood and vessels.
2 Experiment research
2.1 Research on SCD’s therapy on hypertension of SHR and mechanism
(1) The time-effect and dose-effect study of one time treatment of SCD showed that, the time-effect feature of low, middle, high comcentration were similar, they all got the maximum antihypertensive effect at 4h after drug taken, then the blood pressure began to rise, and got back to the level before drug taken at 8h. The dose-effect study shows, the middle, high comcentration groups all had their blood pressure droped obviously at 4h aftert drug taken (p < 0.01), the blood pressure droped about 10mmHg, the low comcentration had no obvious antihypertensive effect.
(2) Between 14-18 week-age, compared with the normal group, the SHR model group’s blood pressure was higher (p<0.01), heart rate was higher (p<0.01), irritable degree was higher (p<0.05 or p<0.01), pain threshold was higher (p<0.01), time persisting on rotary table was shorter (p<0.05 or p<0.01), eyes pop degree was higher (p<0.01), body weight was obviously lower at 18 week-age (p<0.05), and they looked more tentional, often fight between the cagemates, their hair color was more yellow, lacklusterits and losing more, their urine was more yellow, their dejection was more dry. In the 4 weeks treatment, compared with the model group, the SCD group’s blood pressure droped obviously (p<0.01), heart rate and pain threshold had no obvious change, irritable degree reduced (p<0.01), time persisting on rotary table extended (p<0.05), eye pop degree and body weight had no obvious chang, tension and fight reduced, urine color was ligter, dejection was wetter.
(3) Pathomorphology shows, the transverse diameter of ventricular myocyte turned thicker; glomerular sclerosis, atrophy and centralize could be seen in some part of cortex of rats kidney, lymphocytic infiltration could be seen in thestromal; nerve cell addiction and encephalomalacia phenomenon could be seen in some part of the pallium. After 4 weeks treatment, the phenomena above were less in SCD group.
(4) Compared with normal group, both heart weight index and left ventricular mass index of SHR model group inceased (p<0.01), blood plasma AngII level was lower (p<0.01), ET increased (p<0.01), ANP reduced (p<0.01), contents of PRA、CGRP、NO had no obvious differences.
After 4 weeks treatment, compared with model group, the heart weight index and left ventricular mass index had no obvious difference, blood plasma ET level reduced (p<0.01), ANP hoisted (p<0.01), NO hoisted (p<0.01), AngII、PRA、CGRP had no obvious change.
2.2 Research on SCD’s therapy on hypertension of RHR and mechanism
(1) Time-effect study of one time treatment of SCD showed that, the time-effect feature of low, middle, high comcentration were similar, they all got the maximum antihypertensive effect at 4h after drug taken, then the blood pressure began to rise, and got back to the level before drug taken at 8h. The dose-effect study shows, the low, middle, high comcentration groups all had their blood pressure droped obviously 4h aftert drug taken (p<0.05 or p<0.01), the middle comcentration group’s blood pressure droped about 17mmHg, the high comcentration group’s droped 10mmHg, and the low comcentration group’s droped 6mmHg.
(2) Compared with the normal group, the RHR model group’s blood pressure was higher (p<0.01), heart rate was higher (p<0.05 or p<0.01), pain threshold was higher (p<0.05), body weight was obviously lower at 18 weeks age (p<0.01), and it had lower spirits, its hair color was lackluster, its urine was more lighter-colored, it was enuresis being holded up, its dejection was more wet, and had a heavier moldy smell.
In the 4 weeks being treated, compared with the model group, the SCD group’s blood pressure droped obviously (p<0.01), heart rate reduced, body weight hoisted, pain threshold hoisted, time persisting on rotary table extended, and the hair color and enuresis got better.
(3) Pathomorphology shows, the transverse diameter of ventricular myocyte turned thicker; glomerular sclerosis, atrophy and centralize in some part of cortex of rats kidney, lymphocytic infiltration in thestromal and hyaline changes in the artery beside the glomerular could be seen; nerve cell addiction and encephalomalacia phenomenon can be seen in some part of the pallium. After 4 weeks treatment, the phenomena above were less in SCD group.
(4) Compared with normal group, both heart weight index and left ventricular mass index of RHR model group inceased (p<0.01), blood plasma PRA level increased (p<0.01), AngII inctreased (p<0.05), ANP increased (p<0.01), contents of ET, CGRP, NO had no obvious differences.
After 4 weeks treatment, compared with model group, the heart index and left ventricle had no obvious difference, blood plasma PRA level reduced (p<0.01), AngII reduced (p<0.05), ET reduced and NO hoisted (p<0.01), ANP, CGRP had no obvious change.
2.3 Study on individual differences of blood pressure response of SHRs to SCD Although blood pressure decreased obviously in many individuals, there was no obvious difference in the blood pressure of 29% SHR after taken SCD. When the dose was increased or decreased, blood pressure of these insensitive rats still didn’t improve. Conclusion
1 Maladjustment between Qi and blood and obstruct of the vessels are key factors of hypertension pathogenesis. Therapy on Qi,blood and vessels concurrently is SCD’S prescription characteristics;
2 SCD has obvious effect on therapy of hypertension and the effect can last 6 hours, furthermore, its dosage and effect have some relativity;
3 SCD can improve SHR and RHR’s syndrome, which shows its holistic therapy effects;
4 the study illustrates SCD’s mechanism on the therapy of Hypertension mechanism elementarily and finds SCD has different operation mechanism on two hypertension models;
5 In early stage of the disease, SHR’reaction on treatment of hypertension has individual difference.
病机在中医理论中占有十分重要的地位。本课题将高血压的病机按照不同层次,分别讨论,然后探讨各层次间的关系,融会贯通,以期理清病机系统的脉络。
三草降压汤(SCD)是我校名老中医刘渡舟教授创制的经验方,经过大量临床观察证明对高血压病有效。本课题利用现代药理学的方法系统评价该方的降压作用,阐明其降压作用机理,以便为该方的开发和应用奠定现代研究的基础。
利用“病证结合动物模型”进行中医药的基础和应用实验研究,所得研究结果方能揭示辨证论治、方证相应等中医理论的科学内涵,体现中医药治疗的特色与优势。本课题通过宏观表征和行为学指标的观察与微观指标的测定,较系统地研究了自发性高血压大鼠(SHR)和肾性高血压大鼠(RHR)的证候属性,为建立适合中医药研究的动物模型提供了新思路。
目的
1探讨高血压病的病机及SCD治疗高血压的组方机理;
2评价SCD的降压作用;
3阐明SCD治疗高血压病的作用机理;
4初步辨析SHR与RHR模型的证候属性。
方法
1理论研究
通过整理高血压病病机文献,较系统地探讨高血压病病机;基于高血压气、血、脉失调的病机,浅析SCD的组方特点。
2实验研究
采用SHR和两肾一夹(2K1C)法制作的RHR动物模型;采用清醒状态下大鼠尾动脉间接测压法观察降压作用的时效、量效关系及连续给药的降压效果;运用宏观表征和行为学指标,研究SCD对动物模型的证侯属性的影响;运用放射免疫、生物化学的方法检测方药对血浆中的血压调节物质的影响;运用病理切片的方法观察对靶器官损害的影响。
结果
1理论研究
高血压病的病机可以分为基本病机,症状病机,疾病病机,证候病机及微观病机等几个不同层次,气、血失调和脉道不利是该病病机的关键。气、血、脉兼治是SCD的组方特点。
2实验研究
2.1 SCD对SHR大鼠的降压作用及其机理研究
(1) SCD对SHR单次给药的时效关系研究表明,SCD小、中、大3个剂量组时效特点相似,均在给药后4h达到最大降压效果,而后开始回升,8h接近给药前水平。量效关系研究则表明给药后4h,中、大剂量组血压均显著下降(p<0.05),降幅达10mmHg左右,小剂量组无降压作用。
(2) SHR模型组大鼠与正常组相比在14～18周内血压偏高(p<0.01),心率偏高(p<0.01),易激惹程度增加(p<0.05或p<0.01),痛阈提高(p<0.01),旋转时间偏低(p<0.01或p<0.05),眼球突出度偏高(p<0.01),体重偏低,18周龄时有显著性差异(p<0.05),神情较紧张,同笼大鼠间经常有打架现象,毛色发黄而无光泽,毛发脱落较多,小便颜色偏黄,大便颗粒较小、质地较干。
连续给药4周期间,SCD组与模型组相比在给药后血压极显著下降(p<0.01),心率没有明显改变,易激惹程度降低(p<0.01),痛阈无明显差别,旋转时间增加(p<0.05)。眼球突出度未见显著改善,体重无显著变化,紧张、打架现象减少,小便颜色较清,大便较湿润。
(3)病理形态上,SHR模型组可见心肌横径增粗;部分肾脏皮质可见肾小球硬化、萎缩,局部区域肾小球集中现象,间质中有淋巴细胞浸润;大脑皮层局部区域可见嗜神经细胞现象,脑软化等现象。连续给药4周的SCD组上述现象均较少见。
(4)与正常组相比,SHR模型组心脏指数和左心室指数均增加(p<0.01),血浆AngII水平偏低(p<0.01),ET升高(p<0.01),ANP降低(p<0.01),PRA、CGRP、NO含量无明显差异。
与SHR模型组相比,连续给药4周的SCD组的心脏指数和左心室指数无显著差异,血浆ET水平降低(p<0.01),ANP升高(p<0.01),NO升高(p<0.01),AngII、PRA、CGRP无明显变化。
2.2 SCD对RHR大鼠的降压作用及其机理研究
(1) SCD对RHR单次给药的时效关系研究表明,SCD小、中、大3个剂量组时效特点相似,均在给药后4h达到最大降压效果,而后开始回升,8h接近给药前水平。量效关系研究表明,给药后4h,小、中、大剂量组血压均显著下降(p<0.05或p<0.01),中剂量组降幅达17mmHg左右,大剂量组10mmHg,小剂量组6 mmHg。
(2) RHR模型组大鼠在造模后4周～8周期间与正常组相比血压偏高(p<0.01),心率偏高(p<0.01或p<0.05),痛阈偏高(p<0.05),体重偏低,18周龄时有显著性差异(p<0.01),精神较萎靡,毛色无光泽,小便色清,被抓持时遗尿现象较普遍,大便质软,腐臭味重。
连续给药4周期间,SCD组与模型组相比在给药后血压极显著下降(p<0.01),心率减慢(p<0.05),体重增加(p<0.05),痛阈增高(p<0.05),转台旋转时间增长(p<0.05),毛色不泽与遗尿现象亦有改善。
(3)病理形态上,RHR模型组可见心肌横径增粗;部分肾脏皮质可见肾小球硬化、萎缩,局部区域肾小球集中现象,间质中有淋巴细胞浸润,球旁动脉可见玻璃样变性;大脑皮层局部区域可见嗜神经细胞现象,脑软化等现象。连续给药4周后,SCD组上述现象均较少见。
(4)与正常组相比,RHR模型组心脏指数和左心室指数上均增加(p<0.01),血浆PRA水平偏高(P<0.01),AngII偏高(P<0.05),ANP偏高(p<0.01),ET、CGRP、NO无显著差异。
与模型组相比,连续给药4周后,SCD组的心脏指数和左心室指数无显著差异,血浆PRA水平降低(p<0.01),AngII降低(p<0.05),ET降低(p<0.05),NO升高(p<0.05),ANP、CGRP无明显变化。
2.3 SHR大鼠对SCD降压反应的个体差异初探
虽然多数个体给予SCD后血压明显降低,但有29%的SHR大鼠在给药后血压无明显变化,当增大或减小剂量时,这些对药物不敏感的大鼠血压仍没有显著变化。
结论
1气血失调和脉道不利是高血压病病机的关键,气、血、脉兼治是SCD配伍特点;
2 SCD具有明显的降压作用,并且其降压作用显示出一定时效、量效关系;
3 SCD可以改善SHR和RHR的宏观表征及行为,显示出其整体治疗效果;
4初步阐明了SCD的降压作用机理,发现SCD在两种高血压模型中作用机理不同;
5早期SHR对SCD降压反应存在个体差异。
Hypertension is a familiar chronic cardiovascular disease. Not only the incidence of hypertension is high, moreover, the course of the diseases is comparatively longer, its pathology mechanism is complex. This syndrome has many complications, that ofen associates with the damage of important viscera such as heart, brain, kidney and so on, which threatens the health of human being seriously. So the research on the pathogenesis of hypertension and curatives is one of the hotspots of international medical field all over the world. More and more proofs make it clear that T.C.M. has unique advantage on the therapy of hypertension and some available prescriptions have been accumulated in the long-term clinic practices. Reduction analysis of the pathology characteristics of hypertension, comprehensive evaluation the curative effect of clinic effective prescriptions, clarification the mechanism in treating , to study its mechanism in treating essential hypertension, thus development new therapy medicine of hypertension and providing more effective trerapy methods for clinic are important contents of modernization of T.C.M..
Pathogenesis possesses very important postion in T.C.M. theory. This study discussed pathogenesis of essential hypertension respectively according to different levels, then probed into the relationship of various levels in order to ascertain the skeleton venation of pathogenesis system.
San Cao Jiang Ya Tang (SCD) is an experience prescription formulated by famous old doctor of Chinese medicine Liu Du-zhou, a professor of our uviversity, the prescription has been proofed effective in treating hypertension. In this study we maked use of modern pharmacology, comprehensively evaluates this prescription’s effect on hypertension and clarifies its mechanism on therapy of hypertension so as to establish modern research foundation for the development and application of this prescription.
Only through foundmental and applied experiment research by using“animal model with combined syndromes and symptoms”, can the research results reveal the scientific meanings of T.C.M. theories such as treatment based on syndrome differentiation, prescriptions corresponding to syndromes and so on, representing the characterisctis and advantages of traditional chinese medicine. This study comprehensively researched symptom attributes of the spontaneously hypertensive rat (SHR) and the renal hypertensive rat (RHR), providing new thinking on setting up modern animal models for T.C.M. researches.
Objective
1 Discuss the mechanism of hypertension and SCD’s prescription theory in treating hypertension;
2 Evaluate SCD’s effect in treating hypertension;
3 Clarify SCD’s mechanism in treating hypertension;
4 Differentiate Syndrome attributes between SHR and RHR elementarily.
Methods
1 Theoretics research
Systemically discuss the pathogenesis of hypertension through organizing literatures about it.
Preliminary analysis the prescription theory of SCD based on maladjustment pathogenesis of Qi, blood and vessel in hypertension.
2 Experiment research
SHR and two-kindy, one clip (2K1C) RHR were used as animal model. Tail-artery blood pressure measurement for conscious rats was used to observe the time-effect, dose-effect and long-term treatment features of the medicine to the blood pressure of the rats.The effect of SCD to animal model was studied by observeing macro representations and behavior. The blood pressure regulating factors in the plasma was examined by the method of radioimmunoassay and biochemistry. The target-organ damage was observed by pathologic slices making.
Result
1 Theoretics research
Pathogenesis of hypertension can be divided into several different levels, such as basic pathogenesis, pathogenesis of representation, pathogenesis of disease, pathogenesis of syndromes, and micro pathogenesis. Maladjustment between Qi and blood and obstruct of the vessels are the key to the pathology mechanism of this disease. Prescription characteristics of SCD lies in that it can concurrently cure Qi, blood and vessels.
2 Experiment research
2.1 Research on SCD’s therapy on hypertension of SHR and mechanism
(1) The time-effect and dose-effect study of one time treatment of SCD showed that, the time-effect feature of low, middle, high comcentration were similar, they all got the maximum antihypertensive effect at 4h after drug taken, then the blood pressure began to rise, and got back to the level before drug taken at 8h. The dose-effect study shows, the middle, high comcentration groups all had their blood pressure droped obviously at 4h aftert drug taken (p < 0.01), the blood pressure droped about 10mmHg, the low comcentration had no obvious antihypertensive effect.
(2) Between 14-18 week-age, compared with the normal group, the SHR model group’s blood pressure was higher (p<0.01), heart rate was higher (p<0.01), irritable degree was higher (p<0.05 or p<0.01), pain threshold was higher (p<0.01), time persisting on rotary table was shorter (p<0.05 or p<0.01), eyes pop degree was higher (p<0.01), body weight was obviously lower at 18 week-age (p<0.05), and they looked more tentional, often fight between the cagemates, their hair color was more yellow, lacklusterits and losing more, their urine was more yellow, their dejection was more dry. In the 4 weeks treatment, compared with the model group, the SCD group’s blood pressure droped obviously (p<0.01), heart rate and pain threshold had no obvious change, irritable degree reduced (p<0.01), time persisting on rotary table extended (p<0.05), eye pop degree and body weight had no obvious chang, tension and fight reduced, urine color was ligter, dejection was wetter.
(3) Pathomorphology shows, the transverse diameter of ventricular myocyte turned thicker; glomerular sclerosis, atrophy and centralize could be seen in some part of cortex of rats kidney, lymphocytic infiltration could be seen in thestromal; nerve cell addiction and encephalomalacia phenomenon could be seen in some part of the pallium. After 4 weeks treatment, the phenomena above were less in SCD group.
(4) Compared with normal group, both heart weight index and left ventricular mass index of SHR model group inceased (p<0.01), blood plasma AngII level was lower (p<0.01), ET increased (p<0.01), ANP reduced (p<0.01), contents of PRA、CGRP、NO had no obvious differences.
After 4 weeks treatment, compared with model group, the heart weight index and left ventricular mass index had no obvious difference, blood plasma ET level reduced (p<0.01), ANP hoisted (p<0.01), NO hoisted (p<0.01), AngII、PRA、CGRP had no obvious change.
2.2 Research on SCD’s therapy on hypertension of RHR and mechanism
(1) Time-effect study of one time treatment of SCD showed that, the time-effect feature of low, middle, high comcentration were similar, they all got the maximum antihypertensive effect at 4h after drug taken, then the blood pressure began to rise, and got back to the level before drug taken at 8h. The dose-effect study shows, the low, middle, high comcentration groups all had their blood pressure droped obviously 4h aftert drug taken (p<0.05 or p<0.01), the middle comcentration group’s blood pressure droped about 17mmHg, the high comcentration group’s droped 10mmHg, and the low comcentration group’s droped 6mmHg.
(2) Compared with the normal group, the RHR model group’s blood pressure was higher (p<0.01), heart rate was higher (p<0.05 or p<0.01), pain threshold was higher (p<0.05), body weight was obviously lower at 18 weeks age (p<0.01), and it had lower spirits, its hair color was lackluster, its urine was more lighter-colored, it was enuresis being holded up, its dejection was more wet, and had a heavier moldy smell.
In the 4 weeks being treated, compared with the model group, the SCD group’s blood pressure droped obviously (p<0.01), heart rate reduced, body weight hoisted, pain threshold hoisted, time persisting on rotary table extended, and the hair color and enuresis got better.
(3) Pathomorphology shows, the transverse diameter of ventricular myocyte turned thicker; glomerular sclerosis, atrophy and centralize in some part of cortex of rats kidney, lymphocytic infiltration in thestromal and hyaline changes in the artery beside the glomerular could be seen; nerve cell addiction and encephalomalacia phenomenon can be seen in some part of the pallium. After 4 weeks treatment, the phenomena above were less in SCD group.
(4) Compared with normal group, both heart weight index and left ventricular mass index of RHR model group inceased (p<0.01), blood plasma PRA level increased (p<0.01), AngII inctreased (p<0.05), ANP increased (p<0.01), contents of ET, CGRP, NO had no obvious differences.
After 4 weeks treatment, compared with model group, the heart index and left ventricle had no obvious difference, blood plasma PRA level reduced (p<0.01), AngII reduced (p<0.05), ET reduced and NO hoisted (p<0.01), ANP, CGRP had no obvious change.
2.3 Study on individual differences of blood pressure response of SHRs to SCD Although blood pressure decreased obviously in many individuals, there was no obvious difference in the blood pressure of 29% SHR after taken SCD. When the dose was increased or decreased, blood pressure of these insensitive rats still didn’t improve. Conclusion
1 Maladjustment between Qi and blood and obstruct of the vessels are key factors of hypertension pathogenesis. Therapy on Qi,blood and vessels concurrently is SCD’S prescription characteristics;
2 SCD has obvious effect on therapy of hypertension and the effect can last 6 hours, furthermore, its dosage and effect have some relativity;
3 SCD can improve SHR and RHR’s syndrome, which shows its holistic therapy effects;
4 the study illustrates SCD’s mechanism on the therapy of Hypertension mechanism elementarily and finds SCD has different operation mechanism on two hypertension models;
5 In early stage of the disease, SHR’reaction on treatment of hypertension has individual difference.
引文
[1] 陈垦. 刘渡舟教授治疗高血压病的经验. 北京中医学院学报, 1984, 3: 21.
[2] 王长洪. 著名中医学家董建华教授学术经验系列之三——从肝论治高血压病的经验. 辽宁中医杂志, 1999, 26 (9): 390.
[3] 龚一萍. 以肝为中心论治高血压病的理论探讨. 中国中医基础医学杂志, 2000, 6(11): 29-30.
[4] 黄晔.论高血压病不离于肝,不止于肝. 中国中西医结合杂志, 1992, 12(5): 273.
[5] 杨继兵. 从肝论治高血压病浅见. 江西中医学院学报, 2006, 18(4): 17-18.
[6] 方企阳. 补肾活血方治疗高血压病80例. 江苏中医, 1998, 19(11): 22.
[7] 邓铁涛. 邓铁涛临床经验辑要. 北京: 中国医药科技出版社, 1981.
[8] 郭乃光. 健脾化湿法治疗无症状性高血压病30例. 新中医, 2000, 32(10): 35.
[9] 王锁欣. 高血压病从脾论治治疗效果观察. 中医药学刊, 2005, 23(11): 2100.
[10] 高飞. 国际中医心病学术会议述要. 中国医药学报, 1993, 8(2): 53-56.
[11] 陆广莘. 高血压病中西医结合研究中的辨病和辨证问题. 中医杂志, 1980, 21(5): 11.
[12] 孔炳耀. 气血理论在高血压病研究中的应用. 中国中医基础医学杂志, 1998, 4(9): 52-54.
[13] 骆淑媛. 从气血分型治疗高血压病. 吉林中医药, 2004, 24(7): 9-10.
[14] 郭慧君,王知佳.高血压病从瘀论治辨析.中国中医急症, 2006, 15(8): 876-877.
[15] 张国华. 赵立诚从痰论治原发性高血压病经验. 浙江中医杂志, 2006, 41(4): 206-207.
[16] 朱妍, 韩学杰. 高血压病从痰瘀论治的理论研究. 2006, 4(10): 890-891.
[17] 赵瑞红. 中医辨证治疗老年高血压病. 新中医, 2005, 37(11): 83-84.
[18] 鞠大宏, 韩学杰, 谢雁鸣. 高血压病从络论治探讨. 中国中医基础医学杂志, 2001, 7(9): 43-44.
[19] 徐树楠, 王文智. 高血压病从络论治探析. 中医杂志, 2006, 47(1): 3-5.
[1] 冯向阳. 辨证分型治疗高血压病 112 例临床观察. 中医药导报, 2006, 12(8): 34-36.
[2] 张发荣. 高血压病气虚血瘀型特征探析:附357例临床资料. 江苏中医, 1997, 18(9): 38-39.
[3] 徐晓阳, 高瑛. 辨证治疗高血压病 125 例疗效观察. 天津中医, 1998, 15(2): 63-64.
[4] 邓椿松. 辨证治疗高血压病 127 例. 吉林中医药, 2001, 21(2): 17.
[5] 魏霞, 穆广梅. 辨证论治治疗高血压病 300 例. 中医研究, 2003, 16(4): 57-58.
[6] 黎秋明.中医辨证分型治疗高血压病 103 例. 广西中医学院学报, 2003, 6(3): 48-49.
[7] 蔡光先, 朱克俭, 韩育明, 等. 高血压病常见证候临床流行病学观察. 中医杂志, 1999, 40(8): 492-493.
[8] 周文泉, 于向东, 崔玲, 等. 部分高血压病患者证候和危险因素调查. 中国中西医结合杂志, 2002, 22(6): 457-458.
[9] 程文江, 郭峰, 毛军民. 原发性高血压病 602 例中医证候流行病学研究. 浙江中西医结合杂志, 2003, 13(4): 261-262.
[10] 郑峰, 胡世云, 郭进建, 等. 高血压病中医辨证分析. 河北中医, 2000, 22(9): 651-653.
[11] 李泓, 卜秦俐, 胡宪蕴. 原发性高血压肾素-血管紧张素-醛固酮系统及血浆心钠素水平与辨证分型的关系. 中西医结合杂志, 1991, (5): 271-273.
[12] 王爱珍, 蔡治宾, 吴罗杰. 原发性高血压病中医辨证分型与肾素、血管紧张素初探. 中国现代医学杂志, 1998, 8(5): 43-44.
[13] 唐树德. 高血压患者辨证分型与肾素-血管紧张素-醛固酮系统的关系. 辽宁中医杂志, 1985, 12: 4.
[14]李恩等. 肾性高血压中医分型与血浆前列腺素、肾素、血管紧张素II、环核苷酸变化的观察. 中西医结合杂志, 1983, 5(3): 165.
[15] 罗伟, 李保东, 冯小平等. 高血压病虚实辨证与血浆ET、TXB2、6-K-PGF1α水平的关系. 中国中医基础医学杂志, 1999, 5(2): 16-18.
[16] 辛效毅, 张绚邦, 周铭心. 血浆内皮素水平与原发性高血压各中医证候关系的临床研究. 安徽中医临床杂志, 1999, 11(3): 153-154.
[17] 辛效毅, 张绚邦, 周铭心. 高血压病中医证型与血浆 ET、AII 关系研究. 山东中医药大学学报, 2002, 26(2): 123-124.
[18] 林炳辉, 方素钦, 邱山东等. 高血压病中医分型与动态血压、血浆内皮素及降钙素基因相关肽水平的关系. 福建中医学院学报, 2002, 12(12): 6-8.
[19] 张玲瑞, 刘淑云, 白智峰等. 原发性肾性高血压中医辨证分型演变规律与肾素-血管紧张-醛固酮系统、心钠素的关系. 天津中医, 1993, 1: 21.
[20] 张臣, 邢之华, 谭海彦等. 血浆一氧化氮及血压在不同中医证型高血压病患者中的变化. 实用医学杂志, 2005, 21(5): 542-543.
[21] 蒋卫民, 唐蜀华, 陈晓虎. 高血压病辨证分型与胰岛素抵抗关系的初步研究. 中国中医基础医学杂志, 1998, 4(11): 37-39.
[22] 黄俊山, 白介辰, 黄国良, 等. 高血压病患者血清胰岛素、C肽水平与中医辨证分型的关系. 中国中西医结合杂志, 2000, 20(3): 190-191.
[23] 吴奕强, 罗洽华, 唐荣德. 高血压病的血液流变学变化与中医辨证分型的关系.新中医, 1994, 26(3): 10-11.
[24] 陈启后, 周国兰. 高血压病患者辨证分型与血液流变学及血脂关系的研究. 湖南中医杂志, 1990, 6(2): 3-5.
[25] 梁东辉. 高血压病中医辨证分型与血脂水平关系的探讨. 辽宁中医杂志, 1996, 23(4): 148-149.
[26] 白春锦, 周瀛, 王丽. 不同中医证型高血压患者的心血管危险因素分层、高血压分期、分级及血脂等指标变化特征. 2005, 9(23): 145-147.
[27] 郑新, 刘卫红. 高血压病中医辨证分型的血压变化及胸主动脉 CT 改变的研究. 中国中西医结合杂志, 1997, 17(12): 733-734.
[28] 袁丽萍, 方若平. 66 例高血压中医辨证与超声心动图改变对比分析. 云南中医中药杂志, 1998, 19(4): 11-13.
[29] 刘健. 经颅多普勒与高血压病辨证分型的关系. 南京中医药大学学报, 1997, 13(5): 272-273.
[30] 章凤杰, 吴悦. 高血压病经颅多普勒检测结果与辨证分型关系探讨. 江苏中医, 1997, 18(8): 41.
[31] 赵奕,方文岩,赵治. 高血压病中医辨证分型与基底动脉血流动力学探讨. 天津中医药, 2005, 22(4): 297-298.
[32] 张三林, 马峰, 方亚纶, 等. 高血压病人中医辨证分型与甲襞微循环变化的关系.微循环杂志, 1995, 5(1): 39-40.
[33] 曹淞申, 李培祥. 高血压病患者左心室质量的超声心动图观察及其与中医分型的关系. 中国中西医结合杂志, 1995, 15(3): 171.
[34] 王国印. 原发性高血压早期肾损害中医证型与血、尿 β2-MG 及尿 ALB、IgG 的关系. 安徽中医学院学报, 2004, 23(1): 10-12.
[1] 薛冰, 李景新, 陈连璧. 沙苑子总黄酮对 SHR 的降压及血流动力学影响. 中国中药杂志, 2002, 27(11): 855-858.
[2] 李辉, 徐贵成, 刘坤, 等. 息化饮 2 号对高血压模型大鼠的降压实验及活血化瘀作用研究. 北京中医药大学学报, 2003, 26(4): 47-49.
[3] 刘华. 补肾益气活血汤对高血压病相关指标的影响. 浙江中西医结合杂志, 2003, 13(1): 7-9.
[4] 吕圭源, 葛卫红, 石森林, 等. 血灵对大鼠血管平滑肌收缩的影响. 浙江中医学院学报, 2002, 26(4): 51-52.
[5] 丁晓霜. 桂枝茯苓丸对自发性高血压大鼠血管内皮损伤的作用. 国外医学, 中医中药分册, 2002, 24(6): 351-352.
[6] 彭韬, 李庆平. 粉防己碱对肾性高血压大鼠小血管重构的影响. 南京医科大学学报, 2003, 23(1):8-10.
[7] 王博, 张继东, 姜虹, 等. 芩丹胶囊对自发性高血压大鼠主动脉损害的保护和逆转作用. 中国中西医结合杂志, 2006,26(9): 827-830.
[8] 华海清. 决明子的研究与临床应用. 中国中药杂志, 1995, 20(9): 564-567.
[9] 匡锦萍, 胡文江. 山楂叶的利尿作用. 中国中药杂志, 1992, 17(1): 528-528.
[10] Tahri A, Yamani S, Legssyer A, et al. Acute diuretic,natrriuretic and hypotensive effects of a continuous perfusion of aqueous extract of urtica dioica in the rat. Ethnopharmacol, 2000, 73(1-2):95-100.
[11] 陈晓娟, 溪茜, 黄兆富. 中药饮剂对大鼠降压和利尿的效果. 第四军医大学学报, 2000, 21(12): 237-238.
[12] 刘文军, 戴希文, 饶向荣等. 益肾降压方治疗肾实质性高血压的临床研究. 中国中西医结合急救杂志, 2001, 8(3): 131-133.
[13] Kwan CY, Chen YY, Ma MF, et al. Tetrandrine,a Calcium antagonist of Chinese herbal origin,ineraction with vascular muscle alphal-adrenoceptor. Life Sci, 1996, 59: 359-364.
[14] Sotnikova R, Kettmann V, Kostalova D, et al. Relaxant properties of some aporphine alkaloids fromMahonia aquifolium. Methods Find Exp Clin Pharmacol, 1997, 19(9): 589-597.
[15] Kannel WB. Prevalence and natural history of electrocardio-graphic left ventricular hypertrophy. Am J Med, 1983, 75: 4-11.
[16] 刘确, 胡清华, 叶少剑. 甲基莲心碱对内皮素 I 致细胞内钙释放的影响. 中国药理学与毒理学杂志, 1994, 8(3): 227-228.
[17] 王文英, 李祥华. 粉防己碱的心血管药理研究进展. 时珍国医国药, 2005, 16(10): 1039-1041.
[18] 黑爱莲, 孙颂三, 王泽生, 等. 黄芩甙对培养的大鼠主动脉平滑肌细胞内游离钙浓度的影响. 中药药理与临床, 1998, 14(4): 6-8.
[19] 严灿, 邓中炎, 潘毅, 等. 活血祛痰法逆转高血压左心室肥厚的实验研究. 中国中医基础医学杂志, 1999, 5(4):25-27.
[20] 陈素红, 吕圭源, 施斌, 等. 复方决明提取物的降压作用机制研究. 中草药, 2004, 35(2): 180-182.
[21] 肖纯, 金益强, 胡随瑜, 等. 潜阳方对高血压肝阳上亢模型的实验研究. 湖南中医学院学报, 1999, 19(2):8-10.
[22] 严灿, 高敏, 邓中炎, 等. 高血压左心室肥厚患者血浆 P 物质水平的变化及活血祛痰治法的影响. 中国中西医结合杂志, 1998, 18(6): 336-338.
[23] 袁成民. 八物降压冲剂治疗原发性高血压的临床及实验研究. 山东中医药大学学报, 1999, 23(3): 189-192.
[24] 林锦标, 钱士明, 郑开明, 等. 血压平滴鼻剂对高血压大鼠左室肥厚及血浆肾素紧张素的影响. 中国中医药科技, 2000, 7(6): 379.
[25] 陆曙, 杨笛, 翁晓生, 等.降防保心中药复方对肾血管性高血压大鼠肾素-血管紧张素系统的影响. 中国实验方剂学杂志, 1999, 5(3): 26-29.
[26] 张建萍, 张敏, 王正荣. 大川芎丸对血管紧张素Ⅱ受体结合活性的影响. 华西医科大学学报, 2000, 31(4): 452-455.
[27] 耿秀芳, 李桂芝, 康白, 等.银杏叶总黄酮对缩血管物质的影响. 潍坊医学院学报, 2000, 22(3): 192.
[28] 黄文增, 张步延, 王晓君. 当归对高血压症患者血浆内皮素水平的影响, 数理医药学杂志, 1998, 11(4): 367-368.
[29] 刘超, 王勇民, 马世玉. 穿心莲注射液对麻醉大鼠血压的影响. 咸宁医学院学报2000, 14(4): 244-245.
[30] 罗伟, 李保东, 杨瑞华, 等.葛根素治疗高血压的临床研究. 中国中医基础医学杂志, 2000, 6(5): 61-63.
[31] 吴玉生, 杨剑辉, 罗南萍, 等. 天麻钩藤饮治疗原发性高血压患者内皮素、降钙素基因相关肽变化的研究. 1997, 13(6): 45-46.
[32] 刘景超, 杨新华, 肖华云, 等. 降压调脂胶囊对高血压大鼠血压及血清 NO 的影响. 山东中医杂志, 2001, 20(4): 235-236.
[33] 段学忠, 杨丁友, 孙西庆. 益脉降压流浸膏对老年气虚血瘀型高血压病血浆 ET、CGRP 及 NO 的影响. 中国中医药信息杂志, 2000, 7(9): 36-37.
[34] 符德玉, 周端, 顾仁樾. 活血潜镇胶囊对高血压病(血瘀阳亢证)血管内皮细胞功能影响. 上海中医药大学学报, 2000, 14(2): 18-20.
[35] 刘应柯, 刘尚岭, 郭桐生, 等. 参龙降压灵对自发性高血压大鼠血压及血浆 ET、CGRP 含量的影响. 第一军医大学学报, 2000, 20(2): 180-182.
[36] 胡政力, 吴尧忠, 陈彦, 等. “必通汤”降低原发性高血压患者血浆内皮素的初步报告. 江苏中医, 2000, 21(2): 10-11.
[37] 王清海, 黄河清, 陈宁, 等. 血压健 4 号对气虚痰浊型高血压患者血管活性物质的影响. 高血压杂志, 2001, 9(4): 311-312.
[38] 余容, 欧明, 丁有钦, 等. 调平康对高血压病患者红细胞钠含量及血浆心钠素水平的影响, 广州中医学院学报, 1994, 11(4): 220-222.
[39] 张英. 不同疗法对二肾一夹型高血压大鼠血管紧张素Ⅱ、心钠素含量影响的比较.中国针灸, 1996, 16(5): 35-37.
[40] 于向东, 周文泉, 崔玲. 络活胶囊对高血压大鼠血浆肾上腺髓质素和组织因子途径抑制物的影响. 山东中医药大学学报, 2004, 38(1): 56-59.
[41] 杨庆有, 孙慧茹. 天麻钩藤饮对原发性高血压患者TGF-β1、Bcl-2 浓度的影响及临床意义探讨. 中医研究, 2006, 19(7): 24-26.
[42] 龙建军, 郭秀玲, 杨磊, 等. 灵芝对高血压病胰岛素抵抗干预作用的研究. 海南医学, 2001, 12(1): 55-56.
[43] 陈晓虎, 唐蜀华, 李燕, 等. 鬼针草颗粒剂治疗高血压病、高胰岛素血症的临床研究. 南京中医药大学学报, 1998, 14(1): 19-20.
[44] 司晓晨, 潘杨, 程海波, 等. 胰敏胶囊阻止果糖诱导的胰岛素抵抗大鼠高血压的发生研究. 中医药学刊, 2004, 22(2): 250-252.
[45] 牟华明, 戴万亨, 朱慧民, 等. 降压合剂对胰岛素抵抗高血压大鼠作用效应及机制的实验研究. 中国中西医结合急救杂志, 2001, 8(2): 113-115.
[46] 郭伟聪, 刘德桓, 林惠琴, 等. 化瘀浊益肝肾法对高血压病患者左心室肥厚和左室功能的影响. 中医杂志, 2006, 47(10): 752-754.
[47] 李建平, 严灿, 邓中炎, 等. 活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究. 中医杂志, 2000, 41(5): 301-302.
[48] 吴伟, 刘煜德, 陈宏珪, 等. 补肾益心片对肾血管性高血压大鼠的降压作用及保护靶器官的研究. 广州中医药大学学报, 2001, 18(1): 63-66.
[49] 石咏军. 葛根素注射液抑制(延缓)自发性高血压大鼠肾脏血管重塑的实验研究.中国中西医结合肾病杂志, 2002, 3(7): 387-390.
[50] 蒋凤荣, 张旭, 戴晓明. 麦冬对肾性高血压心室肌重构影响的实验研究. 江苏中医药, 2006,27(9): 74-75.
[51] 董科奇, 邓杰. 丹参注射液对自发性高血压大鼠左室肥厚的影响. 浙江中西医结合杂志, 2006, 16(9): 550-551.
[1] 印会河, 童瑶.中医基础理论. 北京: 人民卫生出版社, 2006: 350.
[2] 黄开泰. 论病机层次和要素. 河南中医, 2004, 24(3): 12-13.
[1]李宇航, 牛欣, 李云谷等. 三草降压汤的降压作用探讨. 北京中医药大学学报, 1996, 19(1): 45-46.
[1] 方喜业.医学实验动物学.北京:人民卫生出版社, 1995, 121.
[2] 李俊, 何剑平, 孔炳耀. 高血压病中医动物模型研究现状与应用评价. 广州中医药大学学报, 2002, 19(4): 321-322.
[3] 孔炳耀. 高血压病中医证动物模型的研究和应用. 中国中医基础医学杂志, 2001, 7(7): 39-41.
[4] 廖圣宝, 戴敏, 刘光伟. 二肾一夹高血压大鼠模型中医证候属性的探讨及药物作用观察. 中国中医基础医学杂志, 2003, 9(2): 34-47.
[5] Kleiser B, Reempts JV, Deuren BV, et al. Favourable effect of flunarizine on the recovery from hemiparisis in rats with intracerebral hematomas. Neuroscie nce Letters, 1989, 103: 225-228.
[6] 董昌武. 高血压病左心室肥厚模型病证评价及滋水降火饮干预研究. 北京: 北京中医药大学博士学位论文, 2004.
[7] Fukuda S, Tsuchikura S, Iida H. Age-related changes in blood pressure, hematological values, concentrations of serum biochemical constituents and weights of organs in the SHR/Izm, SHRSP/Izm and WKY/Izm. Exp Anim, 2004, 53(1): 67-72.
[8] Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. Hypertens. 2003, 21(6): 1117-1124.
[9] 鄢东红, 金益强, 肖纯. 自发性高血压大鼠肝阳上亢证模型的复制. 湖南中医学院学报, 1999, 19(4): 35-38.
[10] 何纲, 李桂英, 刘新波. 一种高血压脑出血肝阳上亢证大鼠模型的建立及其评价.中国中西医结合急救杂志, 2005, 12(4): 218-222.
[11] 莫飞智, 李建强, 赖新生. 大鼠高血压血管性痴呆模型的建立及其证型分析. 广西中医学院学报, 2000, (1): 48-51.
[12] 中华人民共和国卫生部制定发布.中药新药临床研究指导原则, 第一辑. 北京:中国医药科技出版社, 1993, 24.
[13] Duncan J, Campbell, Duncan AM, et al. Angiotensin peptide in spontaneously hypertensive and normotensive donryu rats. Hypertension, 1995, 25: 928.
[14] Rajapakse NW, Oliver JJ, Evans RG. Nitric oxide in responses of regional kindey blood flow to vasoactive agents in anesthetized rabbits. Cardiovasc Pharmacol, 2002, 40(2): 210-219.
[15] 于学军, 戚文航, 顾德官. 自发性高血压大鼠左室肥厚及心肌纤维化的态变化. 高血压杂志, 1999, 7(2): 159 162.
[16] 李泓, 卜秦俐, 胡宪蕴. 原发性高血压肾素-血管紧张素-醛固酮系统及血浆心钠素水平与辨证分型的关系. 中西医结合杂志, 1991, (5): 271.
[17] 王爱珍, 蔡治宾, 吴罗杰. 原发性高血压病中医辨证分型与肾素、血管紧张素初探. 中国现代医学杂志, 1998, 8(5):43.
[18] 辛效毅, 张绚邦, 周铭心. 高血压病中医证型与血浆 ET、AII 关系研究. 山东中医药大学学报, 2002, 26(2): 123.
[19] 赵伟康; 顾文聪; 万叔援. 高血压病阴虚火旺患者肾素-血管紧张素-醛固酮系统的观察. 上海中医药杂志.1986(10): 45-47.
[20] 张玲瑞, 刘淑云, 白智峰等. 原发性肾性高血压中医辨证分型衍变规律及实质的探讨. 辽宁中医杂志, 1992, 19(9): 18-21.
[1] 徐叔云, 卞如濂, 陈修. 药理实验方法学. 北京: 人民卫生出版社, 1982: 637.
[2] Nystron HC, Jia J, Johansson M, et al. Neurohormonalin fluences on maintenance and reversal of two-kidney one-clip renal hypertension. Acta Physiol Scand , 2002 , 175 (3): 245-251
[3] 孔炳耀. 高血压病中医证动物模型的研究和应用. 中国中医基础医学杂志, 2001, 7(7): 39-41.
[4] 李俊, 何剑平, 孔炳耀.高血压病中医动物模型研究现状与应用评价. 广州中医药大学学报, 2002, 19(4): 321-322.
[5] 董昌武. 高血压病左心室肥厚模型病证评价及滋水降火饮干预研究. 北京: 北京中医药大学博士学位论文, 2004.
[6] Kato H,Hou J, Aram V, et al Effects Of angiotenism II infusion and inhibition Of NOS on the rat aorta. 1996, 28:153
[7] 董昌武, 高尔鑫. 滋水降火饮对二肾一夹高血压大鼠左室肥厚干预作用的实验研究. 中国中医药科技, 2006, 13(2): 83-85.
[8] 吴辉, 冼绍祥, 黄衍寿. 血管活性物质与原发性高血压中医证型的关系. 四川中医, 2000, 18(10): 11-12.
[9] 郭磊磊, 周英, 庄田田. 高血压中医分型与内皮素、一氧化氮的关系探讨. 贵州医药, 2002, 26(6): 502.
[10] 张玲瑞, 刘淑云, 白智峰等. 原发性肾性高血压中医辨证分型衍变规律及实质的探讨. 辽宁中医杂志, 1992, 19(9): 18-21.
[1]李宇航, 牛欣, 李云谷等. 三草降压汤的降压作用探讨.北京中医药大学学报, 1996, 19(1): 45-46.
[2] 王长洪. 著名中医学家董建华教授学术经验系列之三——从肝论治高血压病的经验. 辽宁中医杂志, 1999, 26 (9): 390.
[3] 龚一萍. 以肝为中心论治高血压病的理论探讨. 中国中医基础医学杂志, 2000, 6(11): 29-30.
[4] 黄晔.论高血压病不离于肝,不止于肝. 中国中西医结合杂志, 1992, 12(5): 273.
[5] 杨继兵. 从肝论治高血压病浅见. 江西中医学院学报, 2006, 18(4): 17-18.
[6] 方企阳. 补肾活血方治疗高血压病80例. 江苏中医, 1998, 19(11): 22.
[7] 邓铁涛. 邓铁涛临床经验辑要. 北京: 中国医药科技出版社, 1981.
[8] 郭乃光. 健脾化湿法治疗无症状性高血压病30例. 新中医, 2000, 32(10): 35.
[9] 王锁欣. 高血压病从脾论治治疗效果观察. 中医药学刊, 2005, 23(11): 2100.
[10] 高飞. 国际中医心病学术会议述要. 中国医药学报, 1993, 8(2): 53-56.
[11] 陆广莘. 高血压病中西医结合研究中的辨病和辨证问题. 中医杂志, 1980, 21(5): 11.
[12] 孔炳耀. 气血理论在高血压病研究中的应用. 中国中医基础医学杂志, 1998, 4(9): 52-54.
[13] 骆淑媛. 从气血分型治疗高血压病. 吉林中医药, 2004, 24(7): 9-10.
[14] 郭慧君,王知佳.高血压病从瘀论治辨析.中国中医急症, 2006, 15(8): 876-877.
[15] 张国华. 赵立诚从痰论治原发性高血压病经验. 浙江中医杂志, 2006, 41(4): 206-207.
[16] 朱妍, 韩学杰. 高血压病从痰瘀论治的理论研究. 2006, 4(10): 890-891.
[17] 赵瑞红. 中医辨证治疗老年高血压病. 新中医, 2005, 37(11): 83-84.
[18] 鞠大宏, 韩学杰, 谢雁鸣. 高血压病从络论治探讨. 中国中医基础医学杂志, 2001, 7(9): 43-44.
[19] 徐树楠, 王文智. 高血压病从络论治探析. 中医杂志, 2006, 47(1): 3-5.
[1] 冯向阳. 辨证分型治疗高血压病 112 例临床观察. 中医药导报, 2006, 12(8): 34-36.
[2] 张发荣. 高血压病气虚血瘀型特征探析:附357例临床资料. 江苏中医, 1997, 18(9): 38-39.
[3] 徐晓阳, 高瑛. 辨证治疗高血压病 125 例疗效观察. 天津中医, 1998, 15(2): 63-64.
[4] 邓椿松. 辨证治疗高血压病 127 例. 吉林中医药, 2001, 21(2): 17.
[5] 魏霞, 穆广梅. 辨证论治治疗高血压病 300 例. 中医研究, 2003, 16(4): 57-58.
[6] 黎秋明.中医辨证分型治疗高血压病 103 例. 广西中医学院学报, 2003, 6(3): 48-49.
[7] 蔡光先, 朱克俭, 韩育明, 等. 高血压病常见证候临床流行病学观察. 中医杂志, 1999, 40(8): 492-493.
[8] 周文泉, 于向东, 崔玲, 等. 部分高血压病患者证候和危险因素调查. 中国中西医结合杂志, 2002, 22(6): 457-458.
[9] 程文江, 郭峰, 毛军民. 原发性高血压病 602 例中医证候流行病学研究. 浙江中西医结合杂志, 2003, 13(4): 261-262.
[10] 郑峰, 胡世云, 郭进建, 等. 高血压病中医辨证分析. 河北中医, 2000, 22(9): 651-653.
[11] 李泓, 卜秦俐, 胡宪蕴. 原发性高血压肾素-血管紧张素-醛固酮系统及血浆心钠素水平与辨证分型的关系. 中西医结合杂志, 1991, (5): 271-273.
[12] 王爱珍, 蔡治宾, 吴罗杰. 原发性高血压病中医辨证分型与肾素、血管紧张素初探. 中国现代医学杂志, 1998, 8(5): 43-44.
[13] 唐树德. 高血压患者辨证分型与肾素-血管紧张素-醛固酮系统的关系. 辽宁中医杂志, 1985, 12: 4.
[14]李恩等. 肾性高血压中医分型与血浆前列腺素、肾素、血管紧张素II、环核苷酸变化的观察. 中西医结合杂志, 1983, 5(3): 165.
[15] 罗伟, 李保东, 冯小平等. 高血压病虚实辨证与血浆ET、TXB2、6-K-PGF1α水平的关系. 中国中医基础医学杂志, 1999, 5(2): 16-18.
[16] 辛效毅, 张绚邦, 周铭心. 血浆内皮素水平与原发性高血压各中医证候关系的临床研究. 安徽中医临床杂志, 1999, 11(3): 153-154.
[17] 辛效毅, 张绚邦, 周铭心. 高血压病中医证型与血浆 ET、AII 关系研究. 山东中医药大学学报, 2002, 26(2): 123-124.
[18] 林炳辉, 方素钦, 邱山东等. 高血压病中医分型与动态血压、血浆内皮素及降钙素基因相关肽水平的关系. 福建中医学院学报, 2002, 12(12): 6-8.
[19] 张玲瑞, 刘淑云, 白智峰等. 原发性肾性高血压中医辨证分型演变规律与肾素-血管紧张-醛固酮系统、心钠素的关系. 天津中医, 1993, 1: 21.
[20] 张臣, 邢之华, 谭海彦等. 血浆一氧化氮及血压在不同中医证型高血压病患者中的变化. 实用医学杂志, 2005, 21(5): 542-543.
[21] 蒋卫民, 唐蜀华, 陈晓虎. 高血压病辨证分型与胰岛素抵抗关系的初步研究. 中国中医基础医学杂志, 1998, 4(11): 37-39.
[22] 黄俊山, 白介辰, 黄国良, 等. 高血压病患者血清胰岛素、C肽水平与中医辨证分型的关系. 中国中西医结合杂志, 2000, 20(3): 190-191.
[23] 吴奕强, 罗洽华, 唐荣德. 高血压病的血液流变学变化与中医辨证分型的关系.新中医, 1994, 26(3): 10-11.
[24] 陈启后, 周国兰. 高血压病患者辨证分型与血液流变学及血脂关系的研究. 湖南中医杂志, 1990, 6(2): 3-5.
[25] 梁东辉. 高血压病中医辨证分型与血脂水平关系的探讨. 辽宁中医杂志, 1996, 23(4): 148-149.
[26] 白春锦, 周瀛, 王丽. 不同中医证型高血压患者的心血管危险因素分层、高血压分期、分级及血脂等指标变化特征. 2005, 9(23): 145-147.
[27] 郑新, 刘卫红. 高血压病中医辨证分型的血压变化及胸主动脉 CT 改变的研究. 中国中西医结合杂志, 1997, 17(12): 733-734.
[28] 袁丽萍, 方若平. 66 例高血压中医辨证与超声心动图改变对比分析. 云南中医中药杂志, 1998, 19(4): 11-13.
[29] 刘健. 经颅多普勒与高血压病辨证分型的关系. 南京中医药大学学报, 1997, 13(5): 272-273.
[30] 章凤杰, 吴悦. 高血压病经颅多普勒检测结果与辨证分型关系探讨. 江苏中医, 1997, 18(8): 41.
[31] 赵奕,方文岩,赵治. 高血压病中医辨证分型与基底动脉血流动力学探讨. 天津中医药, 2005, 22(4): 297-298.
[32] 张三林, 马峰, 方亚纶, 等. 高血压病人中医辨证分型与甲襞微循环变化的关系.微循环杂志, 1995, 5(1): 39-40.
[33] 曹淞申, 李培祥. 高血压病患者左心室质量的超声心动图观察及其与中医分型的关系. 中国中西医结合杂志, 1995, 15(3): 171.
[34] 王国印. 原发性高血压早期肾损害中医证型与血、尿 β2-MG 及尿 ALB、IgG 的关系. 安徽中医学院学报, 2004, 23(1): 10-12.
[1] 薛冰, 李景新, 陈连璧. 沙苑子总黄酮对 SHR 的降压及血流动力学影响. 中国中药杂志, 2002, 27(11): 855-858.
[2] 李辉, 徐贵成, 刘坤, 等. 息化饮 2 号对高血压模型大鼠的降压实验及活血化瘀作用研究. 北京中医药大学学报, 2003, 26(4): 47-49.
[3] 刘华. 补肾益气活血汤对高血压病相关指标的影响. 浙江中西医结合杂志, 2003, 13(1): 7-9.
[4] 吕圭源, 葛卫红, 石森林, 等. 血灵对大鼠血管平滑肌收缩的影响. 浙江中医学院学报, 2002, 26(4): 51-52.
[5] 丁晓霜. 桂枝茯苓丸对自发性高血压大鼠血管内皮损伤的作用. 国外医学, 中医中药分册, 2002, 24(6): 351-352.
[6] 彭韬, 李庆平. 粉防己碱对肾性高血压大鼠小血管重构的影响. 南京医科大学学报, 2003, 23(1):8-10.
[7] 王博, 张继东, 姜虹, 等. 芩丹胶囊对自发性高血压大鼠主动脉损害的保护和逆转作用. 中国中西医结合杂志, 2006,26(9): 827-830.
[8] 华海清. 决明子的研究与临床应用. 中国中药杂志, 1995, 20(9): 564-567.
[9] 匡锦萍, 胡文江. 山楂叶的利尿作用. 中国中药杂志, 1992, 17(1): 528-528.
[10] Tahri A, Yamani S, Legssyer A, et al. Acute diuretic,natrriuretic and hypotensive effects of a continuous perfusion of aqueous extract of urtica dioica in the rat. Ethnopharmacol, 2000, 73(1-2):95-100.
[11] 陈晓娟, 溪茜, 黄兆富. 中药饮剂对大鼠降压和利尿的效果. 第四军医大学学报, 2000, 21(12): 237-238.
[12] 刘文军, 戴希文, 饶向荣等. 益肾降压方治疗肾实质性高血压的临床研究. 中国中西医结合急救杂志, 2001, 8(3): 131-133.
[13] Kwan CY, Chen YY, Ma MF, et al. Tetrandrine,a Calcium antagonist of Chinese herbal origin,ineraction with vascular muscle alphal-adrenoceptor. Life Sci, 1996, 59: 359-364.
[14] Sotnikova R, Kettmann V, Kostalova D, et al. Relaxant properties of some aporphine alkaloids fromMahonia aquifolium. Methods Find Exp Clin Pharmacol, 1997, 19(9): 589-597.
[15] Kannel WB. Prevalence and natural history of electrocardio-graphic left ventricular hypertrophy. Am J Med, 1983, 75: 4-11.
[16] 刘确, 胡清华, 叶少剑. 甲基莲心碱对内皮素 I 致细胞内钙释放的影响. 中国药理学与毒理学杂志, 1994, 8(3): 227-228.
[17] 王文英, 李祥华. 粉防己碱的心血管药理研究进展. 时珍国医国药, 2005, 16(10): 1039-1041.
[18] 黑爱莲, 孙颂三, 王泽生, 等. 黄芩甙对培养的大鼠主动脉平滑肌细胞内游离钙浓度的影响. 中药药理与临床, 1998, 14(4): 6-8.
[19] 严灿, 邓中炎, 潘毅, 等. 活血祛痰法逆转高血压左心室肥厚的实验研究. 中国中医基础医学杂志, 1999, 5(4):25-27.
[20] 陈素红, 吕圭源, 施斌, 等. 复方决明提取物的降压作用机制研究. 中草药, 2004, 35(2): 180-182.
[21] 肖纯, 金益强, 胡随瑜, 等. 潜阳方对高血压肝阳上亢模型的实验研究. 湖南中医学院学报, 1999, 19(2):8-10.
[22] 严灿, 高敏, 邓中炎, 等. 高血压左心室肥厚患者血浆 P 物质水平的变化及活血祛痰治法的影响. 中国中西医结合杂志, 1998, 18(6): 336-338.
[23] 袁成民. 八物降压冲剂治疗原发性高血压的临床及实验研究. 山东中医药大学学报, 1999, 23(3): 189-192.
[24] 林锦标, 钱士明, 郑开明, 等. 血压平滴鼻剂对高血压大鼠左室肥厚及血浆肾素紧张素的影响. 中国中医药科技, 2000, 7(6): 379.
[25] 陆曙, 杨笛, 翁晓生, 等.降防保心中药复方对肾血管性高血压大鼠肾素-血管紧张素系统的影响. 中国实验方剂学杂志, 1999, 5(3): 26-29.
[26] 张建萍, 张敏, 王正荣. 大川芎丸对血管紧张素Ⅱ受体结合活性的影响. 华西医科大学学报, 2000, 31(4): 452-455.
[27] 耿秀芳, 李桂芝, 康白, 等.银杏叶总黄酮对缩血管物质的影响. 潍坊医学院学报, 2000, 22(3): 192.
[28] 黄文增, 张步延, 王晓君. 当归对高血压症患者血浆内皮素水平的影响, 数理医药学杂志, 1998, 11(4): 367-368.
[29] 刘超, 王勇民, 马世玉. 穿心莲注射液对麻醉大鼠血压的影响. 咸宁医学院学报2000, 14(4): 244-245.
[30] 罗伟, 李保东, 杨瑞华, 等.葛根素治疗高血压的临床研究. 中国中医基础医学杂志, 2000, 6(5): 61-63.
[31] 吴玉生, 杨剑辉, 罗南萍, 等. 天麻钩藤饮治疗原发性高血压患者内皮素、降钙素基因相关肽变化的研究. 1997, 13(6): 45-46.
[32] 刘景超, 杨新华, 肖华云, 等. 降压调脂胶囊对高血压大鼠血压及血清 NO 的影响. 山东中医杂志, 2001, 20(4): 235-236.
[33] 段学忠, 杨丁友, 孙西庆. 益脉降压流浸膏对老年气虚血瘀型高血压病血浆 ET、CGRP 及 NO 的影响. 中国中医药信息杂志, 2000, 7(9): 36-37.
[34] 符德玉, 周端, 顾仁樾. 活血潜镇胶囊对高血压病(血瘀阳亢证)血管内皮细胞功能影响. 上海中医药大学学报, 2000, 14(2): 18-20.
[35] 刘应柯, 刘尚岭, 郭桐生, 等. 参龙降压灵对自发性高血压大鼠血压及血浆 ET、CGRP 含量的影响. 第一军医大学学报, 2000, 20(2): 180-182.
[36] 胡政力, 吴尧忠, 陈彦, 等. “必通汤”降低原发性高血压患者血浆内皮素的初步报告. 江苏中医, 2000, 21(2): 10-11.
[37] 王清海, 黄河清, 陈宁, 等. 血压健 4 号对气虚痰浊型高血压患者血管活性物质的影响. 高血压杂志, 2001, 9(4): 311-312.
[38] 余容, 欧明, 丁有钦, 等. 调平康对高血压病患者红细胞钠含量及血浆心钠素水平的影响, 广州中医学院学报, 1994, 11(4): 220-222.
[39] 张英. 不同疗法对二肾一夹型高血压大鼠血管紧张素Ⅱ、心钠素含量影响的比较.中国针灸, 1996, 16(5): 35-37.
[40] 于向东, 周文泉, 崔玲. 络活胶囊对高血压大鼠血浆肾上腺髓质素和组织因子途径抑制物的影响. 山东中医药大学学报, 2004, 38(1): 56-59.
[41] 杨庆有, 孙慧茹. 天麻钩藤饮对原发性高血压患者TGF-β1、Bcl-2 浓度的影响及临床意义探讨. 中医研究, 2006, 19(7): 24-26.
[42] 龙建军, 郭秀玲, 杨磊, 等. 灵芝对高血压病胰岛素抵抗干预作用的研究. 海南医学, 2001, 12(1): 55-56.
[43] 陈晓虎, 唐蜀华, 李燕, 等. 鬼针草颗粒剂治疗高血压病、高胰岛素血症的临床研究. 南京中医药大学学报, 1998, 14(1): 19-20.
[44] 司晓晨, 潘杨, 程海波, 等. 胰敏胶囊阻止果糖诱导的胰岛素抵抗大鼠高血压的发生研究. 中医药学刊, 2004, 22(2): 250-252.
[45] 牟华明, 戴万亨, 朱慧民, 等. 降压合剂对胰岛素抵抗高血压大鼠作用效应及机制的实验研究. 中国中西医结合急救杂志, 2001, 8(2): 113-115.
[46] 郭伟聪, 刘德桓, 林惠琴, 等. 化瘀浊益肝肾法对高血压病患者左心室肥厚和左室功能的影响. 中医杂志, 2006, 47(10): 752-754.
[47] 李建平, 严灿, 邓中炎, 等. 活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究. 中医杂志, 2000, 41(5): 301-302.
[48] 吴伟, 刘煜德, 陈宏珪, 等. 补肾益心片对肾血管性高血压大鼠的降压作用及保护靶器官的研究. 广州中医药大学学报, 2001, 18(1): 63-66.
[49] 石咏军. 葛根素注射液抑制(延缓)自发性高血压大鼠肾脏血管重塑的实验研究.中国中西医结合肾病杂志, 2002, 3(7): 387-390.
[50] 蒋凤荣, 张旭, 戴晓明. 麦冬对肾性高血压心室肌重构影响的实验研究. 江苏中医药, 2006,27(9): 74-75.
[51] 董科奇, 邓杰. 丹参注射液对自发性高血压大鼠左室肥厚的影响. 浙江中西医结合杂志, 2006, 16(9): 550-551.
[1] 印会河, 童瑶.中医基础理论. 北京: 人民卫生出版社, 2006: 350.
[2] 黄开泰. 论病机层次和要素. 河南中医, 2004, 24(3): 12-13.
[1]李宇航, 牛欣, 李云谷等. 三草降压汤的降压作用探讨. 北京中医药大学学报, 1996, 19(1): 45-46.
[1] 方喜业.医学实验动物学.北京:人民卫生出版社, 1995, 121.
[2] 李俊, 何剑平, 孔炳耀. 高血压病中医动物模型研究现状与应用评价. 广州中医药大学学报, 2002, 19(4): 321-322.
[3] 孔炳耀. 高血压病中医证动物模型的研究和应用. 中国中医基础医学杂志, 2001, 7(7): 39-41.
[4] 廖圣宝, 戴敏, 刘光伟. 二肾一夹高血压大鼠模型中医证候属性的探讨及药物作用观察. 中国中医基础医学杂志, 2003, 9(2): 34-47.
[5] Kleiser B, Reempts JV, Deuren BV, et al. Favourable effect of flunarizine on the recovery from hemiparisis in rats with intracerebral hematomas. Neuroscie nce Letters, 1989, 103: 225-228.
[6] 董昌武. 高血压病左心室肥厚模型病证评价及滋水降火饮干预研究. 北京: 北京中医药大学博士学位论文, 2004.
[7] Fukuda S, Tsuchikura S, Iida H. Age-related changes in blood pressure, hematological values, concentrations of serum biochemical constituents and weights of organs in the SHR/Izm, SHRSP/Izm and WKY/Izm. Exp Anim, 2004, 53(1): 67-72.
[8] Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. Hypertens. 2003, 21(6): 1117-1124.
[9] 鄢东红, 金益强, 肖纯. 自发性高血压大鼠肝阳上亢证模型的复制. 湖南中医学院学报, 1999, 19(4): 35-38.
[10] 何纲, 李桂英, 刘新波. 一种高血压脑出血肝阳上亢证大鼠模型的建立及其评价.中国中西医结合急救杂志, 2005, 12(4): 218-222.
[11] 莫飞智, 李建强, 赖新生. 大鼠高血压血管性痴呆模型的建立及其证型分析. 广西中医学院学报, 2000, (1): 48-51.
[12] 中华人民共和国卫生部制定发布.中药新药临床研究指导原则, 第一辑. 北京:中国医药科技出版社, 1993, 24.
[13] Duncan J, Campbell, Duncan AM, et al. Angiotensin peptide in spontaneously hypertensive and normotensive donryu rats. Hypertension, 1995, 25: 928.
[14] Rajapakse NW, Oliver JJ, Evans RG. Nitric oxide in responses of regional kindey blood flow to vasoactive agents in anesthetized rabbits. Cardiovasc Pharmacol, 2002, 40(2): 210-219.
[15] 于学军, 戚文航, 顾德官. 自发性高血压大鼠左室肥厚及心肌纤维化的态变化. 高血压杂志, 1999, 7(2): 159 162.
[16] 李泓, 卜秦俐, 胡宪蕴. 原发性高血压肾素-血管紧张素-醛固酮系统及血浆心钠素水平与辨证分型的关系. 中西医结合杂志, 1991, (5): 271.
[17] 王爱珍, 蔡治宾, 吴罗杰. 原发性高血压病中医辨证分型与肾素、血管紧张素初探. 中国现代医学杂志, 1998, 8(5):43.
[18] 辛效毅, 张绚邦, 周铭心. 高血压病中医证型与血浆 ET、AII 关系研究. 山东中医药大学学报, 2002, 26(2): 123.
[19] 赵伟康; 顾文聪; 万叔援. 高血压病阴虚火旺患者肾素-血管紧张素-醛固酮系统的观察. 上海中医药杂志.1986(10): 45-47.
[20] 张玲瑞, 刘淑云, 白智峰等. 原发性肾性高血压中医辨证分型衍变规律及实质的探讨. 辽宁中医杂志, 1992, 19(9): 18-21.
[1] 徐叔云, 卞如濂, 陈修. 药理实验方法学. 北京: 人民卫生出版社, 1982: 637.
[2] Nystron HC, Jia J, Johansson M, et al. Neurohormonalin fluences on maintenance and reversal of two-kidney one-clip renal hypertension. Acta Physiol Scand , 2002 , 175 (3): 245-251
[3] 孔炳耀. 高血压病中医证动物模型的研究和应用. 中国中医基础医学杂志, 2001, 7(7): 39-41.
[4] 李俊, 何剑平, 孔炳耀.高血压病中医动物模型研究现状与应用评价. 广州中医药大学学报, 2002, 19(4): 321-322.
[5] 董昌武. 高血压病左心室肥厚模型病证评价及滋水降火饮干预研究. 北京: 北京中医药大学博士学位论文, 2004.
[6] Kato H,Hou J, Aram V, et al Effects Of angiotenism II infusion and inhibition Of NOS on the rat aorta. 1996, 28:153
[7] 董昌武, 高尔鑫. 滋水降火饮对二肾一夹高血压大鼠左室肥厚干预作用的实验研究. 中国中医药科技, 2006, 13(2): 83-85.
[8] 吴辉, 冼绍祥, 黄衍寿. 血管活性物质与原发性高血压中医证型的关系. 四川中医, 2000, 18(10): 11-12.
[9] 郭磊磊, 周英, 庄田田. 高血压中医分型与内皮素、一氧化氮的关系探讨. 贵州医药, 2002, 26(6): 502.
[10] 张玲瑞, 刘淑云, 白智峰等. 原发性肾性高血压中医辨证分型衍变规律及实质的探讨. 辽宁中医杂志, 1992, 19(9): 18-21.
[1]李宇航, 牛欣, 李云谷等. 三草降压汤的降压作用探讨.北京中医药大学学报, 1996, 19(1): 45-46.